Uric Acid
10
3
3
5
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
0.0%
0 terminated out of 10 trials
100.0%
+13.5% vs benchmark
30%
3 trials in Phase 3/4
0%
0 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (10)
the Effects of Febuxostat Dose Tapering in Gout Patients Optimally Controlled for 5 Years or More
Uric Acid and Menopausal Age in Acute Kidney Injury
The Effects of Endotracheal Suctioning on Pain and Serum Markers
Uric Acid and Surgical Prognosis
The Effect of Allopurinol on the Risk of Cardiovascular Events in Patients with Cardiovascular Risk
Acute Effects of Tart Cherry on Uric Acid and Biomarkers of CVD Risk in Healthy Individuals
Orlistat Reduces Uric Acid in Overweight/Obese Patients With Hyperuricemia
Value of Uric Acid as Early Predictor of Lupus Nephritis
Research and Development of a New Technology for Detection of Abnormal Excretion of Intestinal Uric Acid Involved in the Incidence of Gout
The Effect of Soursop Supplementation on Blood Pressure, Serum Uric Acid and Kidney Function in Prehypertensive Patients